🔗 Share this article

Given that the US continues making historic revisions to its vaccination guidelines, a particular individual appears in a surprising turn: Tracy Beth Høeg, an American of Danish descent physician and public health researcher who rose to prominence by questioning Covid shots throughout the pandemic and has zeroed in on potential deaths after COVID-19 vaccination in her short position at the US Food and Drug Administration (FDA).

Scheduled Overhauls to Childhood Immunization Schedule

Health officials had intended to reveal sweeping changes to the childhood vaccine schedule earlier this month, synchronizing the US with the Danish national calendar, according to reports – a major change that would put the US out of step with much of the international standard with insufficient data for public health gain. This reveal has been postponed until the coming year.

In place of the top vaccines chief, Høeg is set to speak at the event. She was newly appointed temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to lead the center this calendar year.

A New Direction at the FDA

The acting appointment might represent a tighter collaboration between the pharmaceutical and vaccine branches as Dr. Høeg and Prasad consolidate power at the FDA – and it signals a increased emphasis upon rolling back already-approved immunizations at the FDA.

Dr. Høeg has frequently advocated for discontinuing some pediatric vaccine recommendations in the US in order to be more in line with Denmark's approach, a nation with nationalized medicine and a population approximately the size of Wisconsin’s.

To date public appearances, she has continued to focus on immunizations – typically the purview of Prasad, head of the FDA’s CBER – instead of medication approval.

Concerns Over Qualifications

Høeg has little discernible track record in drug development, regulation or leadership, which has been standard for past heads of the Center for Biologics Evaluation and Research. She has worked at the FDA as a key advisor to the commissioner and the vaccine center since March.

“It seems she lacks to have the requisite experience” for leading the drug-regulation department, said a neurologist and psychiatrist. “She lacks experience running a scientific study. She lacks experience in leading a major agency. She has no expertise in pharmaceutical oversight.”

Previous directors of CBER would “be deeply familiar with regulatory frameworks and the research of drug development”, noted a former acting FDA commissioner. “Frankly, she lacks the sort of resume that former directors who ran the center have had.”

The drug center has an immense range of responsibilities at the agency, she pointed out.

“The public just pays attention on the innovative therapies, but the off-patent medication office approves numerous off-brand pharmaceuticals. There is also a biosimilars division, over-the-counter program and more, and each of these have to be looked after,” Dr. Woodcock explained. “The responsibility you overlook, that’s the thing that I always told people is going to bite you.”

Furthermore, a substantial administrative aspect to the position, which supervises over 5,000 personnel. “It is a massive management job, if you perform it correctly,” the former official concluded.

Agency Reaction and Controversial Initiatives

When asked about questions about Dr. Høeg's credentials and whether this selection represents more teamwork among regulatory chiefs on immunizations, a press secretary stated that the “concerns are based on incorrect presumptions”.

“This background aligns with the responsibilities of her job,” the spokesperson said, pointing to the months Høeg spent counseling the agency head on “pharmaceutical safety and approval science, including predictive safety algorithms and vaccine surveillance”.

In her interim role, Høeg assumes responsibility for the agency head's new fast-track approval initiative, a contentious expedited therapy clearance system that reportedly troubled her predecessors. “By what process are these drugs being selected for this fast-track system? Who is making the calls?” Dr. Howard questioned. “There’s a lot of lack of transparency occurring at the regulatory body right now.”

Broadly speaking, he said, “the agency looks to be trending towards more relaxed oversight of pharmaceuticals, with the exception of vaccines.”

Established Track Record on Immunizations

Regarding vaccines, Høeg has a clearer, if problematic, history, Howard said. She authored a study using non-validated crowd-sourced reports to assess the rate of heart inflammation after COVID-19 immunization. She advised the state of Florida top health official Dr. Joseph Ladapo, who reportedly have modified findings to indicate COVID-19 vaccines are pose a greater threat than they are.

Part of her “desired changes” for the incoming administration included altering guidelines for recently developed shots and discontinuing “unnecessary” immunizations, she remarked post-election on a audio program. At the agency, Dr. Høeg has allegedly suggested excluding young men from obtaining COVID-19 vaccinations.

“She is an thorough ideologue who starts off with her conclusions and tailors the evidence to retrofit the science in a very misleading, fraudulent fashion,” Howard stated.

Gaining Influence and a “Campaign of Retribution”

Høeg became part of fellow dissenters, {like|